55.07
price up icon0.07%   0.04
pre-market  시장 영업 전:  55.07  
loading
전일 마감가:
$55.03
열려 있는:
$55.44
하루 거래량:
386.71K
Relative Volume:
0.76
시가총액:
$3.50B
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-23.94
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
+3.73%
1개월 성능:
+16.26%
6개월 성능:
+20.50%
1년 성능:
+22.62%
1일 변동 폭
Value
$54.36
$55.72
1주일 범위
Value
$52.65
$57.45
52주 변동 폭
Value
$31.42
$58.26

문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile

Name
명칭
Moonlake Immunotherapeutics
Name
전화
41 41 510 8022
Name
주소
DORFSTRASSE 29, ZUG
Name
직원
100
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
MLTX's Discussions on Twitter

MLTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
55.07 3.49B 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-19 업그레이드 Wolfe Research Peer Perform → Outperform
2025-03-18 개시 RBC Capital Mkts Outperform
2025-01-17 업그레이드 Goldman Neutral → Buy
2024-11-05 재개 Wedbush Outperform
2024-08-26 다운그레이드 Wolfe Research Outperform → Peer Perform
2024-06-25 개시 Oppenheimer Outperform
2024-04-02 개시 Goldman Neutral
2024-02-15 개시 Wolfe Research Outperform
2023-12-08 개시 Citigroup Buy
2023-11-02 개시 Stifel Buy
2023-09-14 다운그레이드 Bryan Garnier Buy → Neutral
2023-08-31 개시 Needham Buy
2023-06-15 개시 Barclays Equal Weight
2023-05-01 개시 Guggenheim Buy
2023-03-22 개시 Wedbush Outperform
2023-03-09 개시 BTIG Research Buy
2023-02-14 개시 Cantor Fitzgerald Overweight
2023-02-02 개시 Bryan Garnier Buy
2022-11-11 개시 Jefferies Buy
2022-08-25 개시 SVB Leerink Outperform
2022-07-21 개시 H.C. Wainwright Buy
2022-07-07 개시 Cowen Outperform
모두보기

문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스

pulisher
12:37 PM

How does MoonLake Immunotherapeutics generate profit in a changing economyFree Stock Market Trend Analysis - jammulinksnews.com

12:37 PM
pulisher
Jul 27, 2025

Does MoonLake Immunotherapeutics stock perform well during market downturnsStrong return on assets - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How does MoonLake Immunotherapeutics compare to its industry peersInvest smarter with advanced market data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is MoonLake Immunotherapeutics stock overvalued or undervaluedTake advantage of unprecedented market momentum - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Invest confidently with professional advice - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How strong is MoonLake Immunotherapeutics company’s balance sheetCapitalize on emerging market sectors - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are MoonLake Immunotherapeutics company’s key revenue driversBuild a diversified portfolio for stability - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Does MoonLake Immunotherapeutics (NASDAQ:MLTX) Have A Healthy Balance Sheet? - 富途牛牛

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about MoonLake Immunotherapeutics stockMarket-leading profit generation - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

MoonLake Immunotherapeutics Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 23, 2025

Is MoonLake Immunotherapeutics a good long term investmentBreakthrough stock performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 17, 2025

(MLTX) Trading Advice - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 17, 2025

MoonLake Immunotherap Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Jul 17, 2025
pulisher
Jul 15, 2025

What makes MoonLake Immunotherapeutics stock price move sharplyFree Investment Risk Control - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why MoonLake Immunotherapeutics stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How MoonLake Immunotherapeutics stock performs during market volatilityQuick Profit Idea Stream - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

MoonLake Immunotherap Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

Jul 15, 2025
pulisher
Jul 10, 2025

Merck made $3B+ offer for MoonLake earlier this yearreport - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

MoonLake Immunotherap Getting Closer To Key Technical Benchmark - Investor's Business Daily

Jul 10, 2025
pulisher
Jul 07, 2025

MoonLake Immunotherapeutics Director Makes a Major Stock Move! - TipRanks

Jul 07, 2025
pulisher
Jun 28, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com

Jun 28, 2025
pulisher
Jun 19, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Sector Challenges - geneonline.com

Jun 19, 2025

문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Moukheibir Catherine
Director
Jul 03 '25
Sale
48.79
23,500
1,146,565
0
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):